Haima Therapeutics LLC was founded in 2016 by Drs. Anirban Sen Gupta and Christa Pawlowski, based on groundbreaking work from the Sen Gupta laboratory at CWRU.
Haima is a pre-clinical stage biotechnology company focused on developing bio-inspired therapies to mitigate bleeding in multiple therapeutic indications including traumatic injury, surgery, and thrombocytopenia. Haima has developed a novel, fully-synthetic nanoparticle-based hemostatic technology called SynthoPlate that mitigates bleeding by acting at the site of injury and amplifying your body’s natural clotting mechanisms.
Haima’s research and development efforts for SP have been supported by several federally funded grants including Phase I SBIR awards from DOD, NSF and NIH as well as a service award from the NIH to assist with regulatory strategy and preclinical safety testing.
EXECUTIVE MANAGEMENT TEAM
Michael Bruckman, PhD
Chief Operating Officer
Dr. Bruckman is the COO for Haima Therapeutics after joining in 2018. Mike oversees the company’s business operations and execution of SynthoPlate’s technical development and grant funding strategies. Mike is a seasoned scientist with over 16 years of experience engineering nanoparticles for applications in technology and medicine. Prior to joining Haima, Mike led the commercialization efforts to commercialize a saliva glucose sensor for diabetics as Direct of Research at the technology development startup company, NanoBio Systems. He has 23 publications, 2 book chapters, and 3 patents.
Dr. Bruckman obtained his Ph.D. in organic chemistry from the University at South Carolina and received additional training in Biomedical Engineering and medical device commercialization at CWRU and the Naval Research Laboratory.
Christa Pawlowski, PhD
Co-Founder and Chief Scientific Officer
Dr. Pawlowski has over a decade of drug development experience, with a particular focus on platelet-inspired approaches in nanomedicine. Christa received her PhD in Biomedical Engineering from Case Western Reserve University. As a graduate student and postdoctoral scholar in Anirban Sen Gupta's laboratory, she led the design, fabrication and evaluation of the hemostatic capabilities (both in vitro and in vivo) of the SynthoPlate technology. Dr. Pawlowski also works with BioMotiv, a mission-driven pharmaceutical accelerator focused on accelerating breakthrough discoveries into medicines, as the Director of Project Operations for Allinaire Therapeutics LLC and SapVax LLC.
SCIENTIFIC ADVISORY BOARD
Anirban Sen Gupta, PhD
Inventor, Co-Founder, and Chief Scientific Advisor
Dr. Anirban Sen Gupta is a Professor in the Department of Biomedical Engineering at Case Western Reserve University (CWRU). Dr. Sen Gupta is the inventor of the SynthoPlate technology, co-founder of Haima Therapeutics and serves as their Chief Scientific Advisor. In these capacities, Dr. Sen Gupta provides scientific and technical consultation in the company’s R&D efforts, and also facilitates technology translation and commercialization partnerships with the DoD and NIH. He has dual Bachelor’s degrees in Chemistry and Chemical Engineering, and a Master’s and PhD degrees, both in Chemical Engineering. Dr. Sen Gupta has 15+ years of research experience and expertise in developing novel nanomedicine systems inspired by design cues from blood cells, for therapeutic applications. His research has focused especially on understanding and leveraging blood platelet’s multi-faceted roles: heteromultivalent ligand-receptor interactions among themselves and various matrix proteins, soluble proteins and other cells; platelet secretome in physiological and pathological processes; and platelet’s biophysical (shape, size, stiffness etc.) attributes that influence their dynamic behavior in blood flow. Dr. Sen Gupta’s research is funded by American Heart Association, National Institutes of Health, National Science Foundation and the US Department of Defense. In various aspects of therapeutic development and biomedical technologies, Dr. Sen Gupta has active collaborations with Case School of Medicine, the Cleveland Clinic Foundation, the Cleveland VA Hospital, University of Pittsburgh, Harvard University, University of North Carolina Chapel Hill, University of Colorado Denver, and US Army Institute of Surgical Research. Dr. Sen Gupta holds several patents in nanotechnology and nanomedicine areas. He is also an established educator and provides curricular and mentoring contributions both within the university as well as within several academic societies including Biomedical Engineering Society and Society for Biomaterials.
Jerrold Levy, MD, FAHA, FCCM
Dr. Levy is a critical care physician and cardiac anesthesiologist at Duke University School of Medicine. His expertise is in surgical hemostasis, coagulation and extracorporeal circulation, coagulopathy in the critically ill, shock, anaphylaxis, and he has developed purified and recombinant therapeutic approaches to treat bleeding. He has authored over 450 scientific publications.
Matthew Neal, MD FACS
Dr. Neal is the Roberta G. Simmons Assistant Professor of Surgery at the University of Pittsburgh, and he is a general surgeon and faculty at University of Pittsburgh Medical Center specializing in complex hernia surgery, gastrointestinal surgery, trauma, and emergency general surgery. He is the director of the Pittsburgh Trauma Research Center and he manages an active research team in translational research in bleeding control coagulopathy, massive transfusion, and outcomes following trauma and critical illness. His lab is funded by multiple awards from the NIH, DoD, and private industry. He is heavily involved in several basic research and clinical studies in the areas of pre-hospital interventions for traumatic bleeding including the PAMPer and STAAMP trials. Dr. Neal is also the principal investigator of a large adaptive randomized controlled trial in surgical rehabilitation for high risk surgical patients and is a co-director of the UPMC REMAP clinical trials program.
Philip Spinella, MD
Dr. Spinella is a professor of pediatrics at Washington University in St Louis, and is the Director of the Critical Care Translational Research Program. Dr. Spinella served 15 years in the US Army and separated as a Lieutenant Colonel in 2007. He is a veteran of the Iraq War, where he received a Bronze Star and the Combat Medic Badge for providing care under fire. In collaboration with investigators at the US Army Institute of Surgical Research, his work in the area of the treatment of hemorrhagic shock received the US Army's Best Invention Award in 2008 for his role in the development of the concept of “damage control resuscitation”.
Dr. Spinella co-founded and is co-Chair of the Trauma Hemostasis and Oxygenation Research (THOR) Network, which is an international multidisciplinary network with a mission to improve outcomes for patients with traumatic hemorrhagic shock. Dr. Spinella is also a co-founder of the Pediatric Critical Care Blood Research Network (Blood Net). Blood Net is an international network with a mission to improve outcomes in critically ill children by supporting and performing research in transfusion medicine, hemostasis and blood management. Dr. Spinella is a consultant to the US Army Blood Research Program at the US Army Institute of Surgical Research, and the Norwegian Navy Blood Research Program. In 2015, Dr. Spinella was appointed by the Institute of Medicine as a member on the Committee on Military Trauma Care’s Learning Health System and its Translation to the Civilian Sector. Dr. Spinella is a well-established clinical trialist who has been awarded approximately 20 million dollars in funding from the US Department of Defense and the National Institutes of Health. He has published over 195 manuscripts and 16 chapters in the area of both pediatric and adult critical care.